Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022412 · ClinicalTrials.gov registry record · Phase 2
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 6
- Study locations
NCT00022412 is a Phase 2 study of Prostate Cancer that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 60 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT00022412, a Phase 2 study of Prostate Cancer, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 6
- Study locations
Study Summary
RATIONALE: Doxercalciferol may be an effective way to treat localized prostate cancer before surgery. PURPOSE: Randomized phase II trial to study the effectiveness of giving doxercalciferol before surgery in treating patients who have localized prostate cancer.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
- DIETARY_SUPPLEMENT doxercalciferol
Study Locations (6)
Wisconsin
- Veterans Affairs Medical Center - Madison - Madison
- Meriter Hospital - Madison
- University of Wisconsin Comprehensive Cancer Center - Madison
- Medical College of Wisconsin Cancer Center - Milwaukee
Iowa
- Holden Comprehensive Cancer Center at University of Iowa - Iowa City
New York
- James P. Wilmot Cancer Center at University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2001-08 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022412
The ClinicalTrials.gov registry entry for NCT00022412 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which conventional surgery is the first listed.
NCT00022412 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Wisconsin, Iowa, New York.
Frequently Asked Questions
What is clinical trial NCT00022412 about?
NCT00022412 is a clinical study titled "Doxercalciferol Before Surgery in Treating Localized Prostate Cancer". RATIONALE: Doxercalciferol may be an effective way to treat localized prostate cancer before surgery. PURPOSE: Randomized phase II trial to study the effectiveness of giving doxercalciferol before surgery in treating patients who have localized prostate cancer.
What is the current status of trial NCT00022412?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-08. Estimated completion is 2008-08.
What conditions does trial NCT00022412 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00022412?
The interventions under investigation include: conventional surgery (PROCEDURE), doxercalciferol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00022412?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00022412 being conducted?
This trial has 6 study locations across Iowa, New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.